centogene
reports
first
half
financial
results
testing
expenses
relating
requests
received
internal
research
projects
included
corporate
generate
revenue
allocated
either
two
business
segments
testing
expenses
relating
requests
received
internal
research
projects
included
corporate
generate
revenue
allocated
either
two
business
segments
test
requests
march
may
aggregated
shown
one
column
representing
test
requests
testing
centers
established
test
requests
march
may
aggregated
shown
one
column
representing
test
requests
testing
centers
established
cambridge
mass
rostock
germany
berlin
globe
newswire
centogene
nasdaq
cntg
centogene
company
company
focused
rare
diseases
transforms
world
clinical
genetic
data
actionable
information
patients
physicians
pharmaceutical
companies
today
provided
update
corporate
progress
reported
financial
results
three
six
months
ended
june
cautiously
anticipate
full
year
revenues
within
range
million
revenues
decreased
slightly
compared
recovery
core
businesses
increases
test
requests
new
pharmaceutical
collaborations
r
collaborations
molecular
health
evotec
evidenced
value
centogene
global
proprietary
rare
disease
platform
august
included
data
repository
billion
weighted
data
points
approximately
patients
representing
different
countries
comprehensive
testing
solutions
available
major
travel
hubs
germany
nursing
homes
educational
institutions
well
via
online
marketplace
close
test
requests
received
end
august
test
received
food
drug
administration
fda
emergency
use
authorization
eua
completed
equity
offering
july
proceeds
net
underwriting
discounts
commissions
million
arndt
rolfs
ceo
centogene
said
first
half
shown
resilience
facing
global
pandemic
headwinds
believe
weathered
worst
unprecedented
situation
core
business
rare
disease
space
regained
momentum
continued
expand
efforts
address
urgent
need
reliable
testing
solutions
ultimately
underlines
return
new
normal
patients
physicians
orphan
drug
arndt
rolfs
continued
supported
recovering
diagnostic
volumes
pharma
partnerships
expansion
testing
efforts
remain
confident
outlook
end
year
continue
deliver
commitment
support
patients
around
unwavering
commitment
patients
drives
recovery
company
able
operate
full
capacity
keep
commitment
supporting
patients
around
world
rapidly
responding
novel
coronavirus
deploying
series
testing
initiatives
contribute
important
needs
diagnosis
disease
surveillance
centogene
able
minimize
disruption
core
businesses
maintain
solid
financial
operational
status
global
community
transitioning
new
normal
number
test
requests
core
diagnostics
pharmaceutical
segments
gradually
recovered
company
pharmaceutical
segment
also
regained
momentum
clinical
trials
pharmaceutical
partners
slowly
resuming
collaborations
concluded
company
continuing
expand
medical
genetic
knowledge
rare
genetic
diseases
centogene
expertise
rare
diseases
biomarker
discovery
well
large
volume
datasets
global
proprietary
rare
disease
platform
company
entered
r
collaborations
strategic
partners
molecular
health
evotec
aiming
shorten
diagnostics
odyssey
rare
disease
patients
accelerate
development
new
orphan
drugs
expanding
testing
initiatives
since
commencement
testing
march
centogene
expanded
test
offering
employees
essential
workers
rostock
germany
nursing
homes
high
school
students
throughout
germany
may
june
centogene
announced
partnership
lufthansa
fraport
operator
frankfurt
airport
open
first
test
center
frankfurt
airport
providing
testing
travelers
general
public
subsequent
june
additional
test
centers
set
munich
nuremberg
central
stations
offering
tests
travelers
returning
germany
high
risk
regions
defined
robert
koch
institute
rki
public
health
agency
compiles
statistics
germany
august
centogene
announced
opening
testing
facility
hamburg
airport
offering
testing
passengers
departing
hamburg
returning
hamburg
risk
countries
well
general
public
addition
company
offers
testing
community
collaborations
state
government
pomerania
educational
institutions
companies
well
via
online
marketplace
company
received
test
requests
six
months
ended
june
approximately
test
requests
august
cumulative
basis
test
requests
provided
free
charge
employees
community
research
development
purposes
graph
shows
number
test
requests
received
commencement
testing
march
august
centogene
offers
comprehensive
high
quality
testing
solution
community
includes
test
received
euas
fda
fully
validated
sample
collection
kit
either
used
healthcare
professionals
individuals
secured
digital
platform
including
test
portal
followed
stringent
data
privacy
measures
compliance
general
data
protection
regulation
gdpr
health
insurance
portability
accountability
act
hipaa
allowing
seamless
registration
result
notification
six
months
ended
june
financial
highlights
cash
cash
equivalents
cash
cash
equivalents
june
million
compared
million
december
july
company
completed
public
offering
common
shares
offering
consisting
common
shares
offered
company
common
shares
offered
selling
shareholders
price
public
per
common
share
per
share
aggregate
offering
proceeds
company
net
underwriting
discounts
commissions
amounted
million
revenue
revenue
principally
derived
provision
pharmaceutical
solutions
diagnostic
tests
enabled
knowledge
platform
revenue
three
months
ended
june
million
representing
decrease
compared
three
months
ended
june
pharmaceutical
diagnostics
segments
contributed
respectively
total
revenues
three
months
ended
june
compared
respectively
total
revenues
three
months
ended
june
revenue
pharmaceutical
segment
million
three
months
ended
june
decrease
million
period
revenue
diagnostics
segment
including
revenue
tests
sales
million
million
three
months
ended
june
decrease
million
period
revenue
six
months
ended
june
million
decrease
million
six
months
ended
june
pharmaceutical
diagnostics
segments
contributed
respectively
total
revenues
six
months
ended
june
compared
respectively
total
revenues
six
months
ended
june
revenue
pharmaceutical
segment
million
six
months
ended
june
decrease
million
period
revenue
diagnostics
segment
million
six
months
ended
june
increase
million
period
revenue
tests
sales
six
months
ended
june
million
included
diagnostics
segment
decrease
revenues
pharmaceutical
diagnostics
segments
three
six
months
ended
june
mainly
caused
decrease
sample
volume
related
routine
diagnostics
business
pharmaceutical
collaborations
fee
per
sample
structure
graph
shows
number
test
requests
pharmaceutical
diagnostics
segment
excluding
tests
well
number
test
requests
received
internal
research
projects
three
six
months
ended
june
pharmaceutical
segment
pharmaceutical
segment
provides
variety
services
pharmaceutical
partners
including
target
discovery
early
patient
recruitment
identification
epidemiological
patient
population
sizing
insights
biomarker
discovery
patient
monitoring
information
platforms
access
rare
diseases
patients
biomaterials
ability
develop
proprietary
technologies
including
biomarkers
enable
us
provide
services
pharmaceutical
partners
phases
drug
development
process
well
post
commercialization
particular
capability
collaborate
pharmaceutical
partners
early
stages
drug
development
puts
us
position
provide
support
development
process
increases
potential
secure
collaborations
drugs
revenues
pharmaceutical
segment
generated
primarily
collaboration
agreements
pharmaceutical
partners
structured
fee
per
sample
basis
milestone
basis
fixed
fee
basis
royalty
basis
combination
june
collaborated
pharmaceutical
partners
compared
pharmaceutical
partners
june
active
completed
collaborations
six
months
ended
june
compared
collaboration
six
months
ended
june
graphs
show
revenues
three
six
months
ended
june
resulting
collaborations
pharmaceutical
partners
split
drug
development
stages
well
different
fee
structures
revenues
collaborations
structured
fixed
fee
basis
represented
total
revenues
three
six
months
ended
june
compared
three
six
months
ended
june
revenues
given
fee
structure
provide
us
stable
revenues
cashflow
pharmaceutical
segment
new
existing
clinical
trials
slowed
put
hold
pandemic
significant
impact
collaborations
structured
fee
per
sample
basis
revenues
fee
per
sample
collaborations
million
million
respectively
three
six
months
ended
june
decreased
respectively
compared
periods
revenues
fee
per
sample
collaborations
represented
total
revenues
pharmaceutical
segment
three
six
months
ended
june
decreased
percentage
points
percentage
points
respectively
compared
periods
biomarkers
key
orphan
drug
development
used
support
diagnosis
demonstrate
efficacy
treatment
monitor
progress
rare
disease
patients
biomarkers
also
used
enhance
treatment
solutions
guide
dose
titration
june
biomarker
programs
biomarker
programs
covering
diseases
completed
first
validation
mass
spectrometry
biomarker
programs
biomarkers
used
connection
active
pharmaceutical
collaborations
june
compared
june
since
early
also
started
pursue
metabolomics
approach
establishing
biomarker
discovery
pipeline
rare
hereditary
disease
new
approach
includes
tandem
mass
spectrometry
ion
mobility
quadrupole
mass
spectrometry
methodology
artificial
intelligence
combined
large
volume
datasets
global
rare
disease
platform
proven
successful
identification
new
biomarkers
diagnostics
segment
diagnostics
segment
provides
targeted
genetic
sequencing
diagnostics
services
patients
distribution
partners
clients
typically
physicians
labs
hospitals
revenues
diagnostics
segment
recognized
time
reference
percentage
completion
service
reporting
date
assessed
basis
work
rendered
three
six
months
ended
june
experienced
significant
decreases
tests
requests
received
primary
rare
diseases
testing
products
standard
genetic
testing
including
single
gene
cnv
mutation
quantification
products
panel
sequencing
whole
exome
sequencing
wes
whole
genome
sequencing
wgs
well
testing
nipt
biochemistry
due
pandemic
graphs
show
test
requests
revenues
split
primary
rare
disease
testing
products
three
six
months
ended
june
number
test
requests
received
primary
rare
disease
testing
products
three
six
months
ended
june
decreased
respectively
compared
periods
particular
decreases
test
requests
nipt
product
respectively
three
six
months
ended
june
compared
periods
ended
june
reflecting
strategy
moving
towards
testing
products
provide
larger
quantity
data
wes
wgs
total
number
wes
wgs
test
requests
received
diagnostics
segment
three
six
months
ended
june
represented
respectively
total
primary
test
requests
periods
amounts
increase
percentage
points
percentage
points
respectively
compared
three
six
months
ended
june
addition
total
number
wes
wgs
test
requests
received
six
months
ended
june
increased
compared
periods
ended
june
anticipate
proportion
wes
wgs
percentage
total
test
requests
future
continue
increase
data
biomaterials
collected
diagnostics
services
allow
us
continue
grow
global
biorepository
rare
disease
platform
repository
research
development
expenses
r
r
expenses
increased
million
three
months
ended
june
increased
million
six
months
ended
june
compared
prior
year
periods
increase
primarily
attributable
expenses
associated
expansion
proprietary
information
platform
well
development
new
products
solutions
general
administrative
expenses
g
g
expenses
increased
million
three
months
ended
june
million
six
months
ended
june
compared
prior
year
periods
increases
principally
due
increase
personnel
costs
operating
expenses
result
expansion
business
increase
also
due
costs
operating
public
company
additional
legal
accounting
corporate
governance
investor
relations
expenses
higher
directors
officers
insurance
premiums
general
administrative
expenses
three
six
months
ended
june
also
included
million
expenses
related
free
charge
tests
well
legal
consulting
expenses
million
incurred
relation
offering
completed
july
operating
expenses
taken
consideration
impact
pandemic
global
economy
unforeseeable
potential
magnitude
ultimate
disruptions
different
businesses
assessing
credit
risk
particular
regarding
mena
region
diagnostic
segment
represents
majority
segment
revenue
assessment
resulted
additional
credit
losses
million
million
three
six
months
ended
june
respectively
credit
losses
three
six
months
ended
june
amounted
million
million
respectively
comprehensive
loss
attributable
equity
holders
comprehensive
loss
attributable
equity
holders
three
months
ended
june
million
per
share
compared
million
per
share
prior
year
period
comprehensive
loss
attributable
equity
holders
six
months
ended
june
million
per
share
compared
million
per
share
prior
year
period
basic
diluted
loss
per
share
calculated
dividing
loss
period
attributable
equity
holders
group
weighted
average
number
shares
outstanding
three
six
months
ended
june
three
six
months
ended
june
financial
outlook
pandemic
outbreak
poses
unprecedented
challenges
businesses
particular
healthcare
systems
across
globe
centogene
shown
resilience
first
half
taking
series
measures
minimize
disruptions
business
operations
negative
impact
core
businesses
partially
offset
revenues
resulting
tests
since
july
company
seen
core
business
rare
disease
space
regain
momentum
evidenced
increase
sample
volume
new
collaborations
pharmaceutical
partners
addition
equity
offering
completed
july
strengthened
balance
sheet
company
cautiously
anticipates
revenue
full
year
within
range
million
centogene
anticipates
existing
cash
cash
equivalents
proceeds
offering
enable
company
fund
operating
expenses
capital
expenditure
requirements
months
centogene
consolidated
statements
comprehensive
loss
three
six
months
ended
june
three
months
ended
june
six
months
ended
june
unaudited
thousands
condensed
consolidated
statement
comprehensive
loss
revenue
cost
sales
gross
profit
research
development
expenses
general
administrative
expenses
selling
expenses
operating
income
operating
expenses
real
estate
transfer
tax
expenses
operating
loss
interest
similar
income
interest
similar
expenses
finance
costs
net
loss
taxes
income
tax
benefits
expenses
loss
period
comprehensive
income
loss
total
comprehensive
loss
period
total
comprehensive
loss
period
attributable
equity
holders
parent
loss
per
share
basic
diluted
centogene
supplemental
selected
segment
information
three
six
months
ended
june
three
months
ended
june
six
months
ended
june
unaudited
thousands
revenue
segment
pharmaceutical
diagnostics
total
revenue
three
months
ended
june
six
months
ended
june
unaudited
thousands
segment
adjusted
ebitda
pharmaceutical
diagnostics
total
segment
adjusted
ebitda
reconciliation
segment
adjusted
ebitda
group
loss
period
three
months
ended
june
six
months
ended
june
unaudited
thousands
reported
segment
adjusted
ebitda
corporate
expenses
payment
expenses
depreciation
amortization
operating
loss
finance
costs
net
income
taxes
benefits
expenses
loss
period
centogene
consolidated
statements
financial
position
december
june
assets
dec
june
unaudited
thousands
assets
intangible
assets
property
plant
equipment
assets
assets
current
assets
inventories
trade
receivables
contract
assets
assets
cash
cash
equivalents
equity
liabilities
dec
june
equity
issued
capital
capital
reserve
retained
earnings
reserves
interests
liabilities
loans
lease
liabilities
deferred
tax
liabilities
government
grants
current
liabilities
government
grants
current
loans
lease
liabilities
trade
payables
liabilities
centogene
consolidated
statements
cashflow
six
months
ended
june
six
months
ended
june
unaudited
thousands
loss
taxes
amortization
depreciation
interest
income
interest
expense
expected
credit
loss
allowances
trade
receivables
contract
assets
payment
expenses
real
estate
transfer
tax
expenses
items
changes
operating
assets
liabilities
inventories
trade
receivables
contract
assets
assets
trade
payables
liabilities
cash
flow
used
operating
activities
cash
paid
investments
intangible
assets
cash
paid
investments
property
plant
equipment
grant
received
investment
property
plant
equipment
interest
received
cash
flow
used
investing
activities
cash
paid
acquisition
owned
subsidiary
cash
received
loans
cash
repayment
loans
cash
repayments
lease
liabilities
interest
paid
cash
flow
used
financing
activities
changes
cash
cash
equivalents
cash
cash
equivalents
beginning
period
cash
cash
equivalents
end
period
call
instructions
centogene
host
conference
call
discuss
financial
results
three
six
months
ended
june
wednesday
september
eastern
time
call
accessed
dialing
toll
free
minutes
prior
start
call
providing
conference
id
number
presentation
webcast
conference
call
accessed
investor
relations
page
website
http
centogene
centogene
engages
diagnosis
research
around
rare
diseases
transforming
clinical
genetic
data
actionable
information
patients
physicians
pharmaceutical
companies
goal
bring
rationality
treatment
decisions
accelerate
development
new
orphan
drugs
using
extensive
rare
disease
knowledge
including
epidemiological
clinical
data
well
innovative
biomarkers
centogene
developed
global
proprietary
rare
disease
platform
based
data
repository
billion
weighted
data
points
approximately
patients
representing
different
countries
august
company
platform
includes
epidemiologic
phenotypic
genetic
data
reflects
global
population
also
biobank
patients
blood
samples
centogene
believes
represents
platform
comprehensively
analyzes
data
improve
understanding
rare
hereditary
diseases
aid
identification
patients
improve
pharmaceutical
partners
ability
bring
orphan
drugs
market
august
company
collaborated
pharmaceutical
partners
covering
different
rare
diseases
important
notice
disclaimer
press
release
contains
statements
constitute
forward
looking
statements
term
defined
united
states
private
securities
litigation
reform
act
including
statements
express
company
opinions
expectations
beliefs
plans
objectives
assumptions
projections
regarding
future
events
future
results
contrast
statements
reflect
historical
facts
examples
include
discussion
strategies
financing
plans
growth
opportunities
market
growth
cases
identify
statements
terminology
anticipate
intend
believe
estimate
plan
seek
project
expect
may
would
could
negative
terms
similar
expressions
forward
looking
statements
based
management
current
beliefs
assumptions
information
currently
available
company
however
statements
guarantee
performance
place
undue
reliance
statements
statements
subject
many
risks
uncertainties
variable
circumstances
negative
worldwide
economic
conditions
ongoing
instability
volatility
worldwide
financial
markets
effects
pandemic
business
results
operations
possible
changes
current
proposed
legislation
regulations
policies
pressures
increasing
competition
consolidation
industry
expense
uncertainty
regulatory
approval
including
food
drug
administration
reliance
third
parties
collaboration
partners
including
ability
manage
growth
enter
new
client
relationships
dependency
rare
disease
industry
ability
manage
international
expansion
reliance
key
personnel
reliance
intellectual
property
protection
fluctuations
operating
results
due
effect
exchange
rates
factors
risks
uncertainties
may
cause
statements
inaccurate
readers
cautioned
place
undue
reliance
statements
many
risks
outside
company
control
could
cause
actual
results
differ
materially
thought
would
occur
statements
included
press
release
made
date
hereof
company
undertake
specifically
declines
obligation
update
statements
publicly
announce
results
revisions
statements
reflect
future
events
developments
except
required
law
information
please
refer
risk
factors
section
annual
report
year
ended
december
form
filed
sec
april
form
containing
financial
results
three
months
ended
march
filed
sec
june
current
reports
documents
filed
securities
exchange
commission
sec
may
get
documents
visiting
edgar
sec
website
photos
accompanying
announcement
available
https
newsroom
attachmentng
https
newsroom
attachmentng
https
newsroom
attachmentng
https
newsroom
attachmentng
media
contact
centogene
sun
kim
chief
strategy
investor
relations
officer
fti
consulting
bridie
lawlor
